About this trial

A prospective, single-arm, multi-centre registry to evaluate the safety and performance of Myval THV series using Transcatheter Aortic Valve Implantation (TAVI) procedure in patients with symptomatic severe native aortic valve stenosis.

Eligibility criteria

Qualifiers

Patient over the age of 18 years with symptomatic aortic stenosis (severe AS), intended to perform TAVI procedure using Myval THV series as assessed by Heart Team.

Patient has provided written informed consent as approved by the Ethics Committee (EC)

Patient is willing to undergo all registry procedures and follow-up requirements

Disqualifiers

Patients with hyper sensitivity or allergy to aspirin, heparin, clopidogrel, ticlopidine, cobalt, nickel, chromium, molybdenum or any contrast media.

Ongoing infective endocarditis or any similar infection.

Pregnant or lactating females.

Liver failure (Child-Pugh Class B or C)

Trial design

Treatments tested in this trial

  • Myval THV series

Treatment groups

No treatment groups listed

Locations

6
Unidade Local de Saúde do Lisboa Ocidental E.P.E. - Hospital Santa Cruz2790-134, Carnaxide Portugal
Unidade Local de Saúde de Coimbra3004-561, Coimbra Portugal
Unidade Local de Saúde Alentejo Central E.P.E. - Hospital Espírito Santo7000-811, Evora Portugal
Unidade Local de Saúde de Santa Maria, E.P.E. - Hospital de Santa Maria1649-035, Lisbon Portugal

Sponsors and collaborators

Portuguese Association of Interventional Cardiology

Lead sponsor

Meril Life Sciences Pvt. Ltd.

Collaborator